Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 89 clinical trials
Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML)

The purpose of this study is to show superiority in complete responses of combination therapy MTC plus Glivec in patients with refractory or relapsed AML compared to a historical control which was treated with MTC alone.

serum bilirubin level
refractory acute myeloid leukemia (aml)
mitoxantrone
secondary acute myeloid leukemia
  • 15 views
  • 07 Nov, 2020
  • 1 location
HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt.

patients with relapsed/refractory acute myeloid leukemia (AML) with FLT3mut applying an accelerated titration design.

  • 0 views
  • 27 Jan, 2021
  • 1 location
Azacitidine and Homoharringtonine in JMML

, which exhibited a anticancer mechanism and has been widely used in patients with relapse/refractory acute myeloid leukemia (AML). However, the efficacy of these agents has not been elucidated in

refractory acute myeloid leukemia (aml)
myeloid leukemia
azacitidine
  • 0 views
  • 25 Jan, 2021
  • 1 location
Safety Tolerability PK PD and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Evaluate the safety and tolerability of AMG 427 in adult subjects with relapsed/refractory AML. Estimate the maximum tolerated dose (MTD) and / or a biologically optimal dose (eg, recommended phase 2 dose [RP2D]).

  • 10 views
  • 14 Apr, 2021
  • 20 locations
A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

The purpose of the phase 1 portion (dose escalation) of the study will be to establish an optimally safe and biologically active recommended phase 2 dose (RP2D) and/or to determine maximum tolerated dose (MTD) for gilteritinib in sequential combination with fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG). The purpose of …

blast cells
colony stimulating factor
refractory acute myeloid leukemia (aml)
tyrosine
filgrastim
  • 0 views
  • 05 Mar, 2021
  • 17 locations
A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes

CC-90009-AML-001 is a phase 1, open-label, dose escalation and expansion, study in subjects with relapsed or refractory acute myeloid leukemia and relapsed or refractory high-risk myelodysplastic syndrome.

refractory acute myeloid leukemia (aml)
donor lymphocyte infusion
myeloid leukemia
serum bilirubin level
white blood cell count
  • 0 views
  • 30 Jan, 2021
  • 21 locations
A Clinical Trial to Evaluate Clifutinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia(AML)

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of Clifutinib Besylate in Relapsed/refractory AML patients with FLT3-ITD mutation.

  • 0 views
  • 08 Apr, 2021
  • 1 location
CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

This is a single center, open-label phase 1/2 study to evaluate the safety and efficacy of targeted CD19 chimeric antigen receptor engineered T cell immunotherapy (CART) in the treatment of CD19 positive relapsed or refractory acute myeloid leukemia.

  • 0 views
  • 23 Jan, 2021
  • 1 location
Decitabine+Cladribine+Cytarabine+Granulocyte Colony-stimulating Factor (D-CLAG) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

A prospective, single-arm, multicenter, exploratory study to evaluate the efficacy and safety of D-CLAG regimen in the treatment of relapsed or refractory acute myeloid leukemia

blast cells
colony stimulating factor
refractory acute myeloid leukemia (aml)
decitabine
remission
  • 0 views
  • 26 Jan, 2021
  • 1 location
A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms

This is a Phase 1, 2-part, open-label, multicenter, first-in-human (FIH) study to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of TAS1553 administered orally to participants 18 years of age with relapsed or refractory (R/R) acute myeloid leukemia (AML) or other myeloid neoplasms where approved therapies have …

  • 0 views
  • 31 Jan, 2021
  • 3 locations